These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9667249)

  • 21. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
    Ribrag V; Koscielny S; Vantelon JM; Fermé C; Rideller K; Carde P; Bourhis JH; Munck JN
    Leuk Lymphoma; 2003 Sep; 44(9):1529-33. PubMed ID: 14565655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
    Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Economopoulos T; Raptis SA
    Eur Urol; 2004 Aug; 46(2):216-21. PubMed ID: 15245816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
    Vokes EE; Ansari RH; Masters GA; Hoffman PC; Klepsch A; Ratain MJ; Sciortino DF; Lad TE; Krauss S; Fishkin PA; Golomb HM
    Ann Oncol; 1998 Oct; 9(10):1085-90. PubMed ID: 9834820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infusional vinorelbine in relapsed or refractory lymphomas.
    Sarris AH; Psyrri A; Hagemeister F; Romaguera J; McLaughlin P; Rodriguez MA; Bachier C; Younes A; Mesina O; Oholendt M; Medeiros LJ; Samuels B; Adams LM; Cabanillas F
    Leuk Lymphoma; 2000 Oct; 39(3-4):291-9. PubMed ID: 11342309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
    J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study.
    O'Connor OA; Gerecitano J; Van Deventer H; Hainsworth J; Zullo KM; Saikali K; Seroogy J; Wolff A; Escandón R
    Leuk Lymphoma; 2015; 56(9):2585-91. PubMed ID: 25665464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
    de Jonge MJ; Sparreboom A; Planting AS; van der Burg ME; de Boer-Dennert MM; ter Steeg J; Jacques C; Verweij J
    J Clin Oncol; 2000 Jan; 18(1):187-94. PubMed ID: 10623709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
    Hochster H; Plimack ER; Runowicz CD; Speyer J; Wallach RC; Sorich J; Mandeli J; Wadler S; Wright J; Muggia FM
    J Clin Oncol; 2004 Jan; 22(1):120-6. PubMed ID: 14701774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
    Gianni AM; Bregni M; Siena S; Magni M; Di Nicola M; Lombardi F; Tarella C; Pileri A; Bonadonna G
    J Clin Oncol; 1992 Dec; 10(12):1955-62. PubMed ID: 1280674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
    Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
    J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
    van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
    Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
    J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
    Masuda N; Matsui K; Negoro S; Takifuji N; Takeda K; Yana T; Kobayashi M; Hirashima T; Kusunoki Y; Ushijima S; Kawase I; Tada T; Sawaguchi H; Fukuoka M
    J Clin Oncol; 1998 Oct; 16(10):3329-34. PubMed ID: 9779709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy.
    Grossman SA; Hochberg F; Fisher J; Chen TL; Kim L; Gregory R; Grochow LB; Piantadosi S
    Cancer Chemother Pharmacol; 1998; 42(2):118-26. PubMed ID: 9654111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
    Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.